Evidence map›Paper›PMID 40600058›Full record

ArticlemLife2025

The polyamino-isoprenyl enhancer NV716 enables the antibacterial activity of two families of multi-target inhibitors against the ESKAPEE bacterium

Emma Forest, Jordan Lehoux, Alexandre Guy, Thierry Durand, Stéphane Audebert, Luc Camoin, Christopher D Spilling, Céline Crauste, Stéphane Canaan, Jean Michel Brunel and 2 more

Abstract read
In one paragraph

Article in mLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Emma ForestAix Marseille Univ., CNRS, LISM UMR7255, IMM FR3479 Marseille France.ORCID https://orcid.org/0009-0000-9407-8703
Jordan LehouxIBMM, Univ Montpellier, CNRS, ENSCM Montpellier France.ORCID https://orcid.org/0000-0001-7369-0266
Alexandre GuyIBMM, Univ Montpellier, CNRS, ENSCM Montpellier France.ORCID https://orcid.org/0000-0001-8206-8946
Thierry DurandIBMM, Univ Montpellier, CNRS, ENSCM Montpellier France.ORCID https://orcid.org/0000-0001-6086-7296
Stéphane AudebertAix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique Marseille France.ORCID https://orcid.org/0000-0002-9409-2588
Luc CamoinAix Marseille Univ, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, Marseille Protéomique Marseille France.ORCID https://orcid.org/0000-0002-1230-4787
Christopher D SpillingDepartment of Chemistry and Biochemistry University of Missouri-St. Louis St. Louis Missouri USA.
Céline CrausteIBMM, Univ Montpellier, CNRS, ENSCM Montpellier France.ORCID https://orcid.org/0000-0002-5714-8749
Stéphane CanaanAix Marseille Univ., CNRS, LISM UMR7255, IMM FR3479 Marseille France.ORCID https://orcid.org/0000-0001-7478-300X
Jean Michel BrunelAix Marseille Univ, INSERM, SSA, MCT Marseille France.ORCID https://orcid.org/0000-0002-9355-8980
Jean-Michel BollaAix Marseille Univ, INSERM, SSA, MCT Marseille France.ORCID https://orcid.org/0000-0003-3892-4340
Jean-François CavalierAix Marseille Univ., CNRS, LISM UMR7255, IMM FR3479 Marseille France.ORCID https://orcid.org/0000-0003-0864-8314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gram-negative bacteria are particularly prone to developing antimicrobial resistance (AMR), as evidenced by the WHO's ESKAPEE list of high-priority pathogens. One strategy that has increased is the use of antibiotic enhancers, which can re-empower abandoned or poorly active antibiotics against the resistant strain of interest. In this study, the polyamino-isoprenyl antibiotic enhancer, NV716, was tested in combination with two families of multi-target Ser/Cys-based enzyme inhibitors, the oxadiazolone derivatives (OX) and the Cyclipostins and Cyclophostin analogs (CyC), which are inactive against Gram-negative ESKAPEE bacteria, to potentiate their antibacterial activity and thus make them active against these bacteria. We demonstrated that NV716 potentiates some OX and CyC compounds by permeabilizing the outer membrane and thus by increasing the inhibitor accumulation, as shown by fluorescence microscopy. By using the click-chemistry activity-based protein profiling (ABPP) approach coupled with proteomic analysis, we also confirmed the multi-target nature of the best OX and CyC inhibitors by identifying their target proteins on a bacterial culture of

Indexed as

activity based‐protein profilingantibiotic resistanceCyclipostins and Cyclophostin analogsdrug enhancersoxadiazolone derivatives

Identifiers

PMID40600058
PMCPMC12207906

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.